Thursday, July 30, 2020
Luciole Medical AG, a Swiss medical technology company, and Hôpital Fondation Adolphe de Rothschild announce a collaboration in brain metabolism monitoring research. The two organizations are active in the area of brain hemodynamic and oxygenation monitoring.
“Luciole Medical’s next-generation devices address an area of immense medical need. They enable clinicians to monitor a patient’s brain function in real time and make informed, quick decisions that can be vital for their survival,” added Dr. Nicolas Engrand, deputy head of the Intensive Care Department at Hôpital Fondation Adolphe de Rothschild. “I am impressed with what Luciole Medical team has achieved thus far and am looking forward to working together with Luciole’s scientists.”
Luciole Medical has developed a technology platform that measures brain oxygenation parameters and cerebral blood flow, critical elements necessary for proper brain function, based on the absorbance and transmittance properties of near-infrared light. Luciole Medical is the only company offering a comprehensive oxygenation and hemodynamic solution for intensive care and anesthesiology. Both products have received market authorization in Europe and the company has started the regulatory process in the USA.
“Working together with such a prestigious clinical organization as Hôpital Fondation Rothschild is an honor and a strong recognition of our achievements. It represents an important step in Luciole Medical’s strategy to establish the company as the leading developer of innovative solutions to monitor and evaluate brain function in patients,” commented Dr. Philippe Dro, CEO of Luciole Medical. “We are looking forward to joining forces with the team of Dr. Engrand to progress in the understanding of cerebrovascular pathologies.”
